Her2-positive Lung Cancer Treated With Dedicated Drug

NCT03845270 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer Stage III
HER2 Gene Mutation

Interventions

DRUG: pertuzumab + trastuzumab + docetaxel

Sponsor

Intergroupe Francophone de Cancerologie Thoracique